AcuityMD Raises $80M Series C at Near-Unicorn Valuation to Expand MedTech Platform

According to a recent LinkedIn post from AcuityMD, the company has raised $80M in Series C financing led by StepStone Group with participation from Benchmark, Redpoint, ICONIQ, and Atreides Management. The post indicates that this brings total funding to more than $160M and implies a valuation of about $955M.

The same post suggests that nearly 500 MedTech companies, including 16 of the top 20, are using AcuityMD’s platform to support commercial efforts in a complex and data-fragmented market. This level of customer penetration, if sustained, could support recurring revenue growth and strengthen competitive positioning in the MedTech software and data-analytics ecosystem.

AcuityMD’s post highlights three stated priorities for deploying the new capital: advancing agentic AI capabilities for commercial teams, deepening the company’s underlying data ontology, and expanding its offerings beyond commercial applications to cover the broader MedTech product lifecycle. These initiatives may increase product stickiness, open additional monetization avenues across the value chain, and enhance the company’s ability to defend its near‑unicorn valuation.

From an industry perspective, the focus on integrating claims data, FDA filings, government records, and other market signals suggests an effort to address longstanding information asymmetries in MedTech sales and lifecycle management. If AcuityMD can execute on this strategy at scale, investors may see the potential for operating leverage, higher switching costs for customers, and eventual positioning as a key infrastructure provider in MedTech commercialization and product development.